Researchers evaluated the risk for serious infection in patients with multiple sclerosis treated with ocrelizumab.

Researchers compared the safety and efficacy of intravenous ocrelizumab with oral fingolimod in pediatric relapsing-remitting multiple sclerosis.

Researchers analyzed longitudinal changes in substructure brain volumes after menopause in women with multiple sclerosis.

Researchers evaluated whether ocrelizumab is safe and effective for delaying disability progression in patients with primary progressive multiple sclerosis.

Researchers developed a machine learning-based tool to predict individualized risk for recurrent multiple sclerosis activity after disease modifying therapy discontinuation.

Investigators estimated the prevalence of sleep disorders in patients with multiple sclerosis.

Researchers evaluated whether people with multiple sclerosis receiving disease-modifying therapy first presented with infection symptoms to neurology or non-neurology providers.

Researchers examined use of disease-modifying therapies in women with multiple sclerosis during preconception, pregnancy, and postpartum.

Researchers evaluated whether a deep learning model could distinguish between autoimmune neuroinflammatory disorders based on retinal thickness.

Researchers examined the link between social deprivation and clinical trial participation among patients with multiple sclerosis in the United States and United Kingdom.